Pancreatic Cancer Research

ResearcherUniversité de BordeauxActive in the last 2 years

Dominique Béchade

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9504-920X; OpenAlex author ID A5032600805. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  2. Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should KRAS mutation research be recommended in everyday practice? Co-author DOI 10.1177/17562848231224943↗
  3. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Co-author DOI 10.1038/s41416-022-01713-w↗
  4. Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world A… Co-author DOI 10.1038/s41416-022-01734-5↗
  5. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter … Co-author DOI 10.1016/j.clinre.2019.08.009↗
  6. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Co-author DOI 10.1177/1756284819878660↗
  7. [Strategies for screening for pancreatic adenocarcinoma in high-risk patients: the place of endoscopic ultrasound]. Co-author DOI 10.1016/j.lpm.2010.11.009↗
  8. [Strategies for screening for pancreatic adenocarcinoma in high-risk patients]. Co-author DOI 10.1684/bdc.2011.1396↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Simon Pernot · 6 shared papers, 2019–2025 · strength 0.80
  2. Julien Taı̈eb · 5 shared papers, 2019–2025 · strength 0.59
  3. David Tougeron · 5 shared papers, 2019–2025 · strength 0.59
  4. Anne‐Laure Pointet · 3 shared papers, 2019–2025 · strength 0.33
  5. Isabelle Trouilloud · 3 shared papers, 2019–2025 · strength 0.33
  6. Nicolas Williet · 3 shared papers, 2019–2025 · strength 0.33
  7. Sonia Zaibet · 2 shared papers, 2022 · strength 0.26
  8. Édouard Auclin · 2 shared papers, 2022 · strength 0.26
  9. Astrid Lièvre · 2 shared papers, 2022 · strength 0.26
  10. Matthieu Sarabi · 2 shared papers, 2022 · strength 0.26
  11. Julien Edeline · 2 shared papers, 2022 · strength 0.26
  12. Marine Gilabert · 2 shared papers, 2022 · strength 0.26
  13. Émilie Soularue · 2 shared papers, 2020–2025 · strength 0.26
  14. Jean–Marc Phelip · 2 shared papers, 2019–2025 · strength 0.24
  15. Jeanne Léna · 1 shared paper, 2024 · strength 0.21
  16. Antoîne Italiano · 1 shared paper, 2024 · strength 0.21
  17. Marianne Fonck · 1 shared paper, 2024 · strength 0.21
  18. Gilles Roseau · 1 shared paper, 2024 · strength 0.21
  19. Lola‐Jade Palmieri · 1 shared paper, 2024 · strength 0.21
  20. Raëf Abdallah · 1 shared paper, 2025 · strength 0.16
  21. Alix Portal · 1 shared paper, 2025 · strength 0.16
  22. Franck Bonnetain · 1 shared paper, 2025 · strength 0.16
  23. Laëtitia Dahan · 1 shared paper, 2025 · strength 0.16
  24. Camille Evrard · 1 shared paper, 2025 · strength 0.16
  25. Lysiane Marthey · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.